Laryngeal Cancer & Asbestos

Laryngeal cancer is a malignancy arising in the tissues of the larynx (voice box), most commonly as squamous cell carcinoma. In 2012, the International Agency for Research on Cancer (IARC) formally classified asbestos as a confirmed cause of laryngeal cancer, establishing a direct causal link between asbestos fiber inhalation and the development of this disease.¹

Epidemiological studies demonstrate that asbestos-exposed workers face an approximately 40% increased risk of developing laryngeal cancer compared to unexposed populations. The mechanism is direct: inhaled asbestos fibers pass through the larynx during respiration and can become lodged in laryngeal tissues, where they cause chronic inflammation, cellular damage, and eventually malignant transformation. This risk is particularly pronounced for workers exposed to amphibole fibers.²

The relationship between asbestos exposure and laryngeal cancer is compounded by smoking, the dominant risk factor for this malignancy. When asbestos exposure and tobacco use coexist, the risk increases synergistically — meaning the combined effect is greater than the sum of each risk factor alone. This is especially relevant for occupational cohorts such as shipyard workers and construction tradespeople, where historical smoking rates were high.³

Recognition of the asbestos-laryngeal cancer link has significant legal implications. Individuals who develop laryngeal cancer after documented asbestos exposure may be eligible for compensation through asbestos trust funds, workers' compensation, or personal injury litigation — even when tobacco use was a contributing factor, since asbestos exposure is recognized as an independent causal agent.⁴

Anatomic Subsites of Laryngeal Cancer

• Glottic (vocal cords) — most common subsite (~60% of cases); earliest symptom is hoarseness; best prognosis due to early detection
• Supraglottic (above vocal cords) — ~35% of cases; may present with throat pain, dysphagia, or ear pain; higher rate of lymph node metastasis
• Subglottic (below vocal cords) — rare (~5%); often presents at advanced stage with airway obstruction

• Persistent hoarseness — the most common early symptom, lasting more than 3 weeks
• Sore throat or throat pain — often unilateral and persistent
• Difficulty swallowing (dysphagia) — particularly with supraglottic tumors
• Ear pain (referred otalgia) — pain referred from the larynx via shared nerve pathways
• Neck mass — may indicate lymph node metastasis
• Stridor — noisy breathing indicating airway narrowing in advanced cases
• Unexplained weight loss — systemic sign of advanced disease

Laryngeal cancer results from the interplay of multiple carcinogenic exposures:¹

• Asbestos exposure — inhaled fibers deposit in the larynx, causing chronic inflammation and DNA damage; IARC-confirmed cause
• Tobacco smoking — the dominant risk factor, responsible for the majority of cases
• Alcohol consumption — independent risk factor with synergistic effect alongside smoking
• Occupational exposures — additional agents include strong acid mists, wood dust, and nickel compounds

• Asbestos exposure (occupational or environmental) — ~40% increased risk
• Tobacco use — dose-dependent relationship; 10-fold or greater increased risk in heavy smokers
• Combined asbestos + smoking — synergistic risk amplification
• Heavy alcohol consumption — particularly spirits
• Male sex — incidence 4-5 times higher in men
• Age — peak incidence in the 6th and 7th decades of life

• Direct laryngoscopy — visualization of the larynx with biopsy for histological confirmation
• CT or MRI of the neck — staging and assessment of local extension
• PET-CT — evaluation for distant metastases
• Occupational and exposure history — critical for establishing asbestos as a contributing cause

Laryngeal cancer is staged using the TNM system (AJCC 8th edition):³

• Stage I — tumor confined to one subsite with normal vocal cord mobility
• Stage II — tumor extends to adjacent subsite or impairs cord mobility
• Stage III — cord fixation or limited extension beyond the larynx; or single small lymph node
• Stage IV — extensive local invasion, large or multiple lymph nodes, or distant metastases

• Early-stage (I-II) — radiation therapy alone or endoscopic laser surgery; excellent voice preservation rates
• Locally advanced (III-IV) — concurrent chemoradiation or total laryngectomy with neck dissection
• Voice rehabilitation — tracheoesophageal puncture, electrolarynx, or esophageal speech after laryngectomy
• Immunotherapy — checkpoint inhibitors (pembrolizumab, nivolumab) for recurrent or metastatic disease

Five-year survival rates vary significantly by stage: approximately 75-90% for Stage I glottic cancer, 50-65% for Stage III, and 30-40% for Stage IV. Early detection — prompted by persistent hoarseness — is the single most important prognostic factor. Asbestos-related cases have comparable outcomes to non-asbestos cases when matched for stage and treatment.²

Prevention strategies include eliminating occupational asbestos exposure, smoking cessation, moderating alcohol consumption, and seeking prompt medical evaluation for hoarseness lasting more than three weeks. Workers with combined asbestos and tobacco exposure should be counseled on the synergistic risk.⁴